Does Cardarine Actually Cause Cancer?

Cardarine shows up constantly in performance circles as a fat loss compound that also builds endurance, and the people using it tend to land in one of two camps. The first camp says it causes cancer and refuses to touch it. The second camp says the cancer studies used absurd doses that have nothing to do with human use, so the concern is overblown. Both of those positions are missing something.

Start with what cardarine actually is, because this matters for understanding the risk. It is not a SARM. It works through something called a PPARdelta agonist mechanism, which means it binds to a receptor inside your cells called PPARdelta, and that receptor functions like a switch that controls which genes get activated for fat metabolism and mitochondrial production. When PPARdelta is activated, your body shifts toward burning fat for fuel and building more of the cellular machinery that powers aerobic output. That is why the compound attracted so much interest in the first place.

Now the cancer story. GlaxoSmithKline ran a two-year carcinogenicity study in rats, published as a conference abstract in 2009, and the results were serious enough that the drug never moved forward. Rats given cardarine daily for two years, which represents essentially their entire adult life and scales to roughly 60 years of continuous daily use in a human, developed tumors across multiple organ systems. The affected sites included the liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. The same study was replicated in mice and produced the same multi-organ tumor signal. Two species, the same result.

The detail that matters most is not the list of affected organs. It is the dose response. Tumors appeared at every dose level tested, including the lowest. The researchers never found a threshold below which the signal disappeared. That is what makes a compound like this genuinely difficult to evaluate, because a standard risk model asks where the safe floor is, and in this case the data never located one.

The dose conversion question is where most of the online debate lives, and it deserves a straight answer. The conversion method used in pharmaceutical development to translate animal doses to human equivalents is based on body surface area, not raw milligrams per kilogram, because body surface area tracks more closely with how drugs are metabolized across species. Using that method, the lowest dose that produced tumors in female rats translates to approximately 39 milligrams per day for a 175-pound person. For males it comes out closer to 64 milligrams per day. People using cardarine recreationally are typically taking 10 to 20 milligrams per day, so there is a gap.

But the size of that gap is the point. The gap is roughly two to six times, depending on sex and the dose you are comparing against. The standard safety margin that pharmaceutical development requires before a compound is considered safe for human use is ten times. Cardarine does not clear that bar at any dose that was tested, and the no-effect dose was never found.

There is one more layer that the raw tumor data does not capture. Exercise activates the same PPARdelta receptor that cardarine activates. If PPARdelta activation were simply and directly carcinogenic, you would expect people who exercise heavily to show elevated cancer rates through that pathway, and that is not what the epidemiological data shows. So something about how the body activates PPARdelta through exercise is different from what happens when you activate it pharmacologically.

The mechanism appears to involve something called AMPK, which is a cellular energy sensor that gets activated during exercise alongside PPARdelta. Research published in the Journal of Biological Chemistry in 2021 found that AMPK phosphorylates PPARdelta at a specific site, serine 50, and that phosphorylation suppresses the pro-tumorigenic transcriptional programs that PPARdelta can drive while preserving the metabolic benefits. Think of AMPK as a brake that gets applied at the same time as the gas pedal, so the metabolic engine runs without the downstream signaling that promotes tumor growth.

Cardarine activates the gas pedal without necessarily engaging the brake. The compound pushes PPARdelta activity up but does not trigger the AMPK co-activation that exercise produces. Whether that difference fully explains the tumor findings in rodents, or whether it is one factor among several, is not established. The mechanism is plausible and supported by in vitro and animal work, but it has not been tested in a way that would let you quantify how much cancer risk reduction the AMPK brake actually provides in a living human over years of exposure.

The honest accounting of what the human data shows is limited. One randomized controlled trial published in 2012 ran 268 subjects on up to 10 milligrams per day for 12 weeks and reported no serious adverse events. That study was not designed to detect cancer, was nowhere near long enough to detect cancer, and tells you essentially nothing about long-term oncological risk. Twelve weeks of use in a middle-aged adult does not produce the kind of exposure signal that would show up as a meaningful cancer endpoint.

So the data gap is real, and it runs in both directions. No study has tested cardarine at recreational doses, in healthy humans, over cycle-length timeframes, with cancer as a measured outcome. That study will not happen because no pharmaceutical company has a financial reason to fund it and no ethics board would approve it given the existing animal data.

If you have a personal or family history of cancer, or any known risk factors for the organ systems that showed up in the GSK study, the existing data does not give you a basis for concluding the risk is acceptable. If you have no such history, you are still making a decision inside a genuine information gap, not a gap that favors safety and not a gap that confirms danger, just a gap.

The broader thing to take away is that "the dose was too high" is a reasonable starting point for evaluating animal studies, but it is not a complete argument. The question is not only whether the doses were high. The question is whether a safe dose was ever found. In this case, it was not. That is a different kind of finding than a study that shows harm only at extreme doses and a clean floor below them. And that distinction is what most of the conversation around cardarine keeps skipping over.

---

References

1. Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ 2009. Rat two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting, Abstract #895. Multi-organ tumors at all dose levels in Han Wistar rats including liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. Source
2. Newsholme SJ, Dunsford WS, et al. 2009. Mouse two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting. Multi-organ tumor signal confirmed in mice, consistent with rat findings. Source
3. Ding Y, et al. 2021. AMPK phosphorylates PPARdelta at Serine 50, suppressing pro-tumorigenic transcriptional programs while preserving metabolic benefits. Journal of Biological Chemistry, 297:100954. Source
4. Reagan-Shaw S, Nihal M, Ahmad N 2008. Dose translation from animal to human studies revisited. FASEB Journal, 223:659-661. FDA-preferred body surface area normalization method for interspecies dose conversion. Source
5. Olson EJ, Pearce GL, Jones NP, Sprecher DL 2012. Human RCT, 268 subjects, up to 10 mg/day for 12 weeks. No serious adverse events but far too short for cancer assessment. Arteriosclerosis, Thrombosis, and Vascular Biology, 329:2289-2294. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness